Transgene pockets $22.2 million from selling part of stake in Tasly

5 August 2020

Shares of French biotech Transgene (Euronext Paris: TNG) were up 8.6% at 1.62 euros this morning, after the company revealed late Tuesday that it has raised $22.2 billion from the sale of 10.3 million shares of its minority stake in Tasly BioPharmaceuticals to a Chinese investment fund.

The shares that have been sold represent 38% of Transgene’s total holding in China-based Tasly BioPharmaceuticals. The transaction enhances the company’s cash position and strengthens its financial visibility until 2022.

Following this share sale, Transgene holds 17.1 million shares in Tasly BioPharmaceuticals, equivalent to 1.58% of the latter’s capital. Transgene’s remaining shareholding in Tasly BioPharmaceuticals would be valued at around $36.9 million based on the price of the current share sale.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK